Spruce Biosciences (SPRB)
(Real Time Quote from BATS)
$0.47 USD
-0.01 (-1.88%)
Updated Aug 28, 2024 01:32 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Price, Consensus and EPS Surprise
SPRB 0.47 -0.01(-1.88%)
Will SPRB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SPRB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SPRB
Spruce Biosciences, Inc. (SPRB) Reports Q2 Loss, Tops Revenue Estimates
G1 Therapeutics (GTHX) Reports Q2 Loss, Tops Revenue Estimates
SPRB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Spruce Biosciences, Inc. (SPRB) Reports Q1 Loss, Tops Revenue Estimates
Pfizer (PFE) Q1 Earnings and Revenues Beat Estimates
Spruce Biosciences (SPRB) Upgraded to Buy: Here's What You Should Know
Other News for SPRB
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Spruce Biosciences (SPRB) and Envista Holdings (NVST)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Kronos Bio (KRON), Spruce Biosciences (SPRB) and scPharmaceuticals (SCPH)
Spruce Biosciences GAAP EPS of -$0.22 beats by $0.01, revenue of $1.61M beats by $0.69M
Analysts Offer Insights on Healthcare Companies: Meiragtx Holdings (MGTX), Spruce Biosciences (SPRB) and Gossamer Bio (GOSS)
Spruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates